NCT07806448Completed
Impact of Asprosin and Neuregulin 4 on Metabolic Parameters, Anthropometric Indices and Body Composition After Laparoscopic Sleeve Gastrectomy
The Impact of Asprosin and Neuregulin 4 on Metabolic Parameters, Anthropometric Indices and Body Composition After Laparoscopic Sleeve Gastrectomy: Protocol for a Prospective Longitudinal Cohort Study With a Non-obese Reference Group and a Nested Mixed-meal Sub-study (ASPEN-SG)
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
Asprosin and neuregulin 4 (NRG4) sit on opposing arms of adipose endocrine physiology. Asprosin is a fasting-induced, white adipose-derived glucogenic and orexigenic hormone that rises with adiposity and insulin resistance. NRG4 is a brown and beige adipose-derived, anti-lipogenic and hepatoprotective factor that falls with adiposity. Both have been examined separately after metabolic and bariatric surgery, but never in the same cohort, and existing surgical data cannot separate a weight-loss-dependent effect from an effect of the operation itself. Objectives: To quantify the change in fasting serum asprosin and NRG4 over twelve months after laparoscopic sleeve gastrectomy (LSG); to determine whether those changes are associated with metabolic improvement independently of weight loss; and to characterise their relationship with anthropometric indices and body composition.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 160 (actual)
- First submitted
- 1 Sept 2026
- Start date
- 17 Jul 2025
- Primary completion date
- 17 Jul 2026
- Lead sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
- Diseases
- Obesity
- NCT number
- NCT07806448
What you commit to
- Study type: Observational
- Participants enrolled: 160
- From 17 Jul 2025 to the primary completion date, 17 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- revisional or emergency surgery
- SGLT2 inhibitor or thiazolidinedione
- systemic corticosteroid or immunosuppressive therapy
Other illness
- type 1 diabetes or insulin-treated type 2 diabetes
- chronic liver disease of non-metabolic aetiology or cirrhosis
- FBN1-related connective tissue disorder
- active or recent malignancy
- adrenal or gonadal disorder
Other
- use within three months of a GLP-1 receptor agonist
- dual GIP/GLP-1 receptor agonist
- alcohol intake above 20 g/day in women or 30 g/day in men
- estimated glomerular filtration rate below 60 mL/min/1.73 m²
- untreated thyroid
- pregnancy or lactation
- any device precluding bioelectrical impedance analysis
- high-sensitivity C-reactive protein above 10 mg/L at baseline
Who the study is looking for
- body mass index of at least 35 kg/m² regardless of the presence
- absence or severity of obesity-related comorbidities
- should be considered at 30-34.9 kg/m² in the presence of metabolic disease
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The surgical department of Medical Research Institute Hospital, Alexandria University Coordinator of this site? Confirm its status | Alexandria | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.